TP53突变状态对ALK重排非小细胞肺癌系统治疗结局的影响
该研究在集中诊断平台上对216例IIIB/IV期ALK重排NSCLC患者行二代测序与FISH分析,评估合并突变对系统治疗结局的影响。致病性TP53突变频率为23.8%,其他合并突变罕见。ALK/TP53共突变患者的中位PFS和OS均显著低于TP53野生型患者,且该差异在各治疗相关亚组中均得到验证。
要点
- ALK重排NSCLC中TP53共突变频率为23.8%,其他合并突变罕见。
- ALK/TP53共突变者中位PFS 3.9个月 vs 10.3个月,OS 15.0个月 vs 50.0个月。
- 差异在化疗、克唑替尼±化疗及后续新一代ALK抑制剂亚组中均被证实。
核心结论
- 在ALK重排NSCLC中,合并TP53突变预示系统治疗结局不佳。
- 作者建议未来研究探索其分子机制并改善ALK/TP53共突变亚组的治疗结局。
研究设计与样本
- 对ALK重排IIIB/IV期NSCLC患者在集中诊断平台行二代测序和FISH分析。
- 共纳入216例ALK重排NSCLC患者,分析总队列及治疗相关亚组的PFS和OS。
- 采用Cox回归分析排除混杂因素。
主要发现
- 致病性TP53突变频率为23.8%,其他合并突变属罕见事件。
- ALK/TP53共突变患者中位PFS 3.9个月(95%CI 2.4-5.6) vs TP53野生型10.3个月(95%CI 8.6-12.0),P<0.001。
- 中位OS 15.0个月(95%CI 5.0-24.9) vs 50.0个月(95%CI 22.9-77.1),P=0.002。
- 仅化疗亚组一线PFS 2.6个月(95%CI 1.3-4.1) vs 6.2个月(95%CI 1.8-10.5),P=0.021;OS 2.0个月(95%CI 0.0-4.6) vs 9.0个月(95%CI 6.1-11.9),P=0.035。
- 克唑替尼±化疗亚组PFS 5.0个月(95%CI 2.9-7.2) vs 14.0个月(95%CI 8.0-20.1),P<0.001;OS 17.0个月(95%CI 6.7-27.3) vs 未达到,P=0.049。
关键数值与推荐
- TP53突变频率23.8%(216例ALK重排NSCLC患者中)。
- 克唑替尼后序贯新一代ALK抑制剂亚组:PFS 5.4个月(95%CI 0.1-10.7) vs 9.9个月(95%CI 6.4-13.5),P=0.039;OS 7.0个月 vs 50.0个月(95%CI未达到),P=0.001。
临床怎么用
- 对ALK重排NSCLC患者可考虑检测TP53突变状态以辅助预后分层。
- ALK/TP53共突变患者系统治疗预后较差,需更密切随访并探索强化治疗策略。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders. RESULTS: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4-5.6) versus 10.3 months (95% CI: 8.6-12.0), P < 0.001; OS 15.0 months (95% CI: 5.0-24.9) versus 50.0 months (95% CI: 22.9-77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3-4.1) versus 6.2 months (95% CI: 1.8-10.5), P = 0.021; OS 2.0 months (95% CI: 0.0-4.6) versus 9.0 months (95% CI: 6.1-11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9-7.2) versus 14.0 months (95% CI: 8.0-20.1), P < 0.001; OS 17.0 months (95% CI: 6.7-27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1-10.7) versus 9.9 months (95% CI: 6.4-13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001). CONCLUSIONS: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
引用
- Kron A, Alidousty C, Scheffler M, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018. PMID: 30165392. doi:10.1093/annonc/mdy333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。